About Medinol

Ingenuity for life

The Medinol Group is Dedicated to the Science of Cardiovascular Intervention

Since its founding in 1992 by Dr. Judith Richter and Dr. Jacob (Kobi) Richter, Medinol has been at the forefront of pioneering new stent system technology.

Backed by over 400 patents, the company has delivered over 2,000,000 stents to date and its cutting-edge cardiovascular intervention technology continues to demonstrate extraordinary clinical results.

Medinol’s products constantly stretch the limits of innovation; the scientific spirit that led the company to pioneer the revolutionary NIR stent in 1996 still drives its multidisciplinary team today.

The company is privately-held, and the full scope of its activity – including research, development, quality control, regulatory affairs, clinical trials, manufacturing, marketing, and sales – is conducted in-house.

NIR Stent

The NIR stent was first introduced in 1996 and revolutionized interventional cardiology.
Medinol's NIR stent was the first stent to provide both flexibility and robust scaffolding enabling treatment of longer lesions in more complex anatomies.

This breakthrough vastly expanded the patient base suitable for stenting and positioned stenting as the favored treatment over more risky, complex and expensive surgical intervention.

In-line with Medinol’s commitment to proven clinical excellence, NIR stents are some of the most clinically-studied Bare Metal Stents ever produced. Since 1995, NIR and its successors have been examined in over 25 clinical studies involving more than 5000 patients.


Under Dr. Judith Richter and Dr. Jacob (Kobi) Richter leadership, Medinol fundamentally transformed the interventional cardiology industry through innovation and revolutionary technology. With an extremely cost-efficient manufacturing operation and best-in-class products, Dr. Judith Richter and Dr. Jacob (Kobi) Richter grew Medinol to become a significant international player in the stenting industry, highly reputable for its commitment to promote scientific advances and health.

Dr. Judith Richter
Co-Founder and Executive Board Co-Chairman
Dr. Judith Richter is an accomplished entrepreneur and among the most distinguished business leaders within the Israeli industry. Dr. Richter was Medinol's Chief Executive Officer until recently attaining Emeritus status.

Read More
Dr. Kobi Richter
Co-Founder and Executive Board Co-Chairman
Dr. Jacob (Kobi) Richter was the company's Chief Technology Officer and led Medinol's R&D, Manufacturing, Quality Control and Regulatory Affairs departments.

Read More

NIR Legacy of

With over two million NIR stents delivered to date, our sixth generation coronary stent, the EluNIR™, proudly continues the NIR legacy of innovation


The first coronary stent to excel in both flexibility and scaffolding

NIR Elite

Improved deliverability and conformability


New design for exceptional balance between conformability and scaffolding


CoCr alloy offering thinner struts and improved crossing profile


Flexx2 technology for unmatched flexibility, pushability and ease-of-delivery


The first elastomeric Drug Eluting Stent


Enhancing deliverability and redefining visibility


Revolutionary Hybrid DES

Accessibility Toolbar